Clinical Trials on Carcinoma. Hepatocellular in Hong Kong

Total 638 results

Bristol-Myers Squibb

Completed

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC (BRISK TA)

Hepatocellular Carcinoma

United States, Argentina, Australia, Canada, China, France, Hong Kong, Italy, Japan, Korea, Republic of, Taiwan, Thailand, Spain
National Cancer Institute (NCI)

Completed

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (MAESTRO HN)

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditions

United States, China
Translational Research in Oncology
Bayer

Recruiting

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 (REPLACE)

Carcinoma, Hepatocellular

Korea, Republic of, United States, Taiwan, Spain, Japan, France, Georgia, Belgium, Germany, Turkey, Italy, Hong Kong, Serbia
AstraZeneca

Active, not recruiting

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)

Hepatocellular Carcinoma

United States, Canada, Brazil, France, Italy, Russian Federation, Spain, Vietnam, Korea, Republic of, China, Germany, Ukraine, Japan, Hong Kong, Taiwan, India, Thailand
Exelixis

Completed

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

Hepatocellular Carcinoma

Belgium, Hong Kong, Korea, Republic of, Canada, France, Taiwan, United States, Germany, Spain, United Kingdom, Singapore, Australia, Italy, Netherlands, Poland, Turkey, Ireland, New Zealand, Romania
Novartis Pharmaceuticals

Recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...

Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States
Boehringer Ingelheim

Completed

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Carcinoma, Non-Small-Cell Lung

Hong Kong, China, Taiwan, Singapore, India
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVC Differentiated Thyroid Gland Carcinoma... and other conditions

United States, Taiwan, Australia, Singapore, China
Bristol-Myers Squibb

Completed

Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer (CheckMate 078)

Non-Small Cell Lung Cancer

China, Hong Kong, Russian Federation, Singapore
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Australia, Austria, Belgium, Canada, China, Czechia, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
AVEO Pharmaceuticals, Inc.

Completed

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Lung Neoplasms | Respiratory Tract Neoplasms | Lung Cancer | Carcinoma, Non-Small Cell-Lung

Hong Kong, Korea, Republic of, Malaysia, Philippines, Singapore, Taiwan, Thailand
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)

Hepatocellular Carcinoma

United States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
Viracta Therapeutics, Inc.

Recruiting

Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC

Nasopharyngeal Carcinoma | EBV-Related Gastric Carcinoma | EBV-Related Leiomyosarcoma | EBV Related Carcinoma | EBV-Related Sarcoma

United States, Hong Kong, Taiwan, Korea, Republic of, Singapore, Australia, Canada, Malaysia
Hoffmann-La Roche

Completed

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, France, United Kingdom, Hong Kong
First Affiliated Hospital, Sun Yat-Sen University

Recruiting

ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma

Locally Advanced Nasopharyngeal Carcinoma

China
Novartis Pharmaceuticals

Completed

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. (EVOLVE-1)

Carcinoma

China, Italy, Taiwan, Germany, Hungary, Belgium, Spain, Australia, Austria, France, Hong Kong, Thailand, Korea, Republic of, Canada, Japan, Israel, United States, Greece
Li Zhang, MD

Recruiting

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
AstraZeneca

Active, not recruiting

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)

Hepatocellular Carcinoma

United States, Canada, France, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, India, Japan, Mexico, Russian Federation, China, Hong Kong, Australia, Spain, Singapore
Bayer

Completed

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Belgium, France, Switzerland, Germany, United States, Austria, New Zealand, Hungary, Korea, Republic of, Italy, Hong Kong, Thailand, Spain, Taiwan, Japan, Czechia, United Kingdom
Bristol-Myers Squibb

Recruiting

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106)

Carcinoma, Hepatocellular

United States, Taiwan, Spain, France, Korea, Republic of, Germany, Puerto Rico, China, Japan, Canada, Hong Kong, Australia, Poland, Singapore, Italy
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

China, Hong Kong, Taiwan, Philippines, Thailand, Korea, Republic of, Indonesia
AstraZeneca

Active, not recruiting

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2)

Hepatocellular Carcinoma

United States, France, Germany, Italy, Canada, Taiwan, Thailand, Vietnam, Korea, Republic of, Brazil, Japan, Peru, Poland, Russian Federation, Turkey, China, Hong Kong, Puerto Rico, Austria, Australia, India, Philippines, Singapore, E...
Sun Yat-sen University

Recruiting

Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

Small Cell Lung Carcinoma

China
Qianfoshan Hospital

Recruiting

Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC

Extensive Small Cell Lung Cancer

China
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)

Hepatocellular Carcinoma

Germany, Romania, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Hong Kong, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Switzerland and more
Sanofi
Groupe Oncologie Radiotherapie Tete et Cou

Completed

TRACE: Tirapazamine-Radiation And Cisplatin Evaluation (TRACE)

Head and Neck Squamous Cell Carcinoma

United States, France, Canada, Poland, Germany, Spain, Switzerland, Singapore, Taiwan, Argentina, Hungary, Italy, Chile, Hong Kong, South Africa, Australia, New Zealand
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)

Hepatocellular Carcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Georgia, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Philippines, ... and more
Bayer

Completed

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Belgium, China, Hong Kong, Switzerland, Japan, France, Spain, Germany, United States, Austria, Czechia, United Kingdom, Korea, Republic of, Thailand, New Zealand, Hungary, Israel, Italy, Taiwan, Singapore, Turkey
Pfizer

Terminated

Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

Carcinoma, Hepatocellular

United States, Belgium, Spain, Canada, Italy, Korea, Republic of, Poland, Turkey, Germany, Singapore, Taiwan, China, France, Hong Kong, South Africa, Australia, Japan, Sweden, Malaysia, Philippines, Thailand, Russian Federation, United...
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan, Korea, Republic of, Switzerland, Hong Kong
Hoffmann-La Roche

Completed

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) (MERIT)

Non-Squamous Non-Small Cell Lung Cancer

Hong Kong, Spain, Russian Federation, France, Bulgaria, Germany, Estonia, Italy, Poland, Taiwan, United Kingdom, Singapore, Ireland, Belgium
AstraZeneca

Completed

Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer (THASSOS-INTL)

Non-small Cell Lung Cancer

Turkey, Hong Kong, Australia, Egypt, India, Kuwait, United Arab Emirates
Eli Lilly and Company

Completed

A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung

China, Taiwan, Australia, Korea, Republic of, Egypt, Romania, India, Turkey
Zhujiang Hospital
Guangdong Xiangxue Precision Medical Technology Co., Ltd.; Xiangxue Life Science... and other collaborators

Completed

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

Solid Tumor | Breast Cancer Stage IV | Gastric Cancer Stage IV | Ovarian Cancer Stage IV | Liver Cancer Stage IV | Esophageal Cancer, Stage IV | Bone and Soft Tissue Tumors | Bladder Carcinoma Stage IV | Prostate Carcinoma Stage IV | Thyroid Cancer Stage IV

China
Shenzhen People's Hospital
Sixth Affiliated Hospital, Sun Yat-sen University; The University of Hong Kong-Shenzhen...

Recruiting

Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer (NeoCaCRT)

Locally Advanced Rectal Carcinoma

China
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

Hepatocellular Carcinoma

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, New Zealand, Norway, Poland, Russian Federation, Spai... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX)

Hepatocellular Carcinoma | Liver Cancer

United States, Canada, Germany, France, Russian Federation, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Hong Kong, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Puerto Rico, Romania, Sing... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave150)

Carcinoma, Hepatocellular

United States, Korea, Republic of, United Kingdom, Canada, China, Hong Kong, Taiwan, Australia, Italy, Spain, Czechia, Japan, Singapore, France, Germany, Poland, Russian Federation
Novartis Pharmaceuticals

Completed

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

United States, China, Taiwan, Singapore, Hong Kong, Thailand, France
Soon Chun Hyang University

Unknown

Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture

Bile Duct Obstruction | Klatskin's Tumor

Korea, Republic of
Bayer

Completed

Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (SEARCH)

Carcinoma, Hepatocellular

Belgium, France, Spain, Hong Kong, United States, Canada, Germany, Greece, New Zealand, Russian Federation, Australia, Taiwan, Austria, United Kingdom, China, Israel, Korea, Republic of, Bulgaria, Brazil, Poland, Italy, Colombia, South... and more
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, Hong Kong
Yale University
National Cancer Institute (NCI)

Recruiting

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Stage IV Prostate Adenocarcinoma AJCC v7

United States, Taiwan, Korea, Republic of, Australia, China, Japan
Gynecologic Oncology Trial & Investigation Consortium
Japanese Gynecologic Oncology Group

Completed

Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial (iPocc)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

Japan, United States, Hong Kong, Korea, Republic of, New Zealand, Singapore
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA)

Non-Small Cell Lung Cancer (NSCLC)

Korea, Republic of, Malaysia, Taiwan, Thailand, Hong Kong, Singapore, Canada
The Catholic University of Korea
Janssen Korea, Ltd., Korea

Completed

Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection

Early Gastric Adenocarcinoma | Adenocarcinoma, Tubular

Korea, Republic of
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Active, not recruiting

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Recurrent Colon Carcinoma | Metastatic Colorectal Carcinoma | Stage IV Colon Cancer AJCC v7 | Stage IVA Colon Cancer AJCC v7 | Stage IVB Colon Cancer AJCC v7 | Refractory Colorectal Carcinoma

United States
Samyang Biopharmaceuticals Corporation

Completed

A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer (GPMOC202)

Ovarian Cancer

Korea, Republic of
Eisai Inc.

Completed

Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

KIF5B-RET-Positive Adenocarcinoma of the Lung

United States, Hong Kong, Japan, Taiwan, Singapore
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Neoplasms | Kidney Neoplasms | Breast Neoplasms | Pancreatic Neuroendocine Neoplasms (pNETs)

France, Germany, United States, Netherlands, Italy, Spain, United Kingdom, Hong Kong, Hungary

Clinical Trials on Carcinoma. Hepatocellular in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations